|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Brundage MD, Davies D and Mackillop WJ:
Prognostic factors in non-small cell lung cancer: a decade of
progress. Chest. 122:1037–1057. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Folkman J: Clinical applications of
research on angiogenesis. N Engl J Med. 333:1757–1763. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Saphir A: Angiogenesis the unifying
concept in cancer. J Natl Cancer Inst. 89:1658–1659.
1995.PubMed/NCBI
|
|
5
|
Chen HJ, Treweeke AT, Ke YQ, West DC and
Toh CH: Angiogenically active vascular endothelial growth factor is
over-expressed in malignant human and rat prostate carcinoma cells.
Br J Cancer. 82:1694–1701. 2000.PubMed/NCBI
|
|
6
|
George ML, Tutton MG, Janssen F, Arnaout
A, Abulafi AM, Eccles SA and Swift RI: VEGF-A, VEGF-C, and VEGF-D
in colorectal cancer progression. Neoplasia. 3:420–427. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nishida N, Yano H, Komai K, Nishida T,
Kamura T and Kojiro M: Vascular endothelial growth factor C and
vascular endothelial growth factor receptor 2 are related closely
to the prognosis of patients with ovarian carcinoma. Cancer.
101:1364–1374. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ohta Y, Endo Y, Tanaka M, Shimizu J, Oda
M, Hayashi Y, Watanabe Y and Sasaki T: Significance of vascular
endothelial growth factor messenger RNA expression in primary lung
cancer. Clin Cancer Res. 2:1411–1416. 1996.PubMed/NCBI
|
|
9
|
Jin Y, Xiong X, Su Y, Hu J and Tao X:
Serum vascular endothelial growth factor levels in patients with
non-small cell lung cancer and its relations to the micrometastasis
in peripheral blood. J Huazhong Univ Sci Technolog Med Sci.
29:462–465. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niki T, Iba S, Tokunou M, Yamada T,
Matsuno Y and Hirohashi S: Expression of vascular endothelial
growth factors A, B, C, and D and their relationships to lymph node
status in lung adenocarcinoma. Clin Cancer Res. 6:2431–2439.
2000.PubMed/NCBI
|
|
11
|
Smith WL and Langenbach R: Why there are
two cyclooxygenase isozymes. J Clin Invest. 107:1491–1495. 2011.
View Article : Google Scholar
|
|
12
|
Lim SC, Park SY and Do NY: Correlation of
cyclooxygenase-2 pathway and VEGF expression in head and neck
squamous cell carcinoma. Oncol Rep. 10:1073–1079. 2003.PubMed/NCBI
|
|
13
|
Von Rahden BH, Stein HJ, Pühringer F, Koch
I, Langer R, Piontek G, Siewert JR, Höfler H and Sarbia M:
Coexpression of cyclooxygenases (COX-1, COX-2) and vascular
endothelial growth factors (VEGF-A, VEGF-C) in esophageal
adenocarcinoma. Cancer Res. 65:5038–5044. 2005.PubMed/NCBI
|
|
14
|
Cianchi F, Cortesini C, Bechi P, Fantappiè
O, Messerini L, Vannacci A, Sardi I, Baroni G, Boddi V, Mazzanti R
and Masini E: Up-regulation of cyclooxygenase-2 gene expression
correlates with tumour angiogenesis in human colorectal cancer.
Gastroenterology. 121:1339–1347. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang SP, Wu MS, Shun CT, Wang HP, Hsieh
CY, Kuo ML and Lin JT: Cyclooxygenase-2 increases hypoxia inducible
factor-1 and vascular endothelial growth factor to promote
angiogenesis in gastric carcinoma. J Biomed Sci. 12:229–241. 2005.
View Article : Google Scholar
|
|
16
|
Dirim A, Haberal AN, Goren MR, Tekin MI,
Peskircioglu L, Demirhan B and Ozkardes H: VEGF, COX-2, and PCNA
expression in renal cell carcinoma subtypes and their prognostic
value. Int Urol Nephrol. 40:861–868. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HS, Youm HR, Lee JS, Min KW, Chung JH
and Park CS: Correlation between cyclooxygenase-2 and tumor
angiogenesis in non-small cell lung cancer. Lung Cancer.
42:163–170. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rundhaug JE: Matrix metalloproteinases and
angiogenesis. J Cell Mol Med. 9:267–285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rooprai HK, Rucklidge GJ, Panou C and
Pilkington GJ: The effects of exogenous growth factors on matrix
metalloproteinase secretion by human brain tumor cells. Br J
Cancer. 82:52–55. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lee KS, Min KH, Kim SR, Park SJ, Park HS,
Jin GY and Lee YC: Vascular endothelial growth factor modulates
matrix metalloproteinase-9 expression in asthma. Am J Respir Crit
Care Med. 174:161–170. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zilfou JT and Lowe SW: Tumor suppressive
functions of p53. Cold Spring Harb Perspect Biol1. a001883
View Article : Google Scholar : 2009.PubMed/NCBI
|
|
22
|
Mukhopadhyay D, Tsiokas L and Sukhatme VP:
Wild-type p53 and v-Src exert opposing influences on human vascular
endothelial growth factor gene expression. Cancer Res.
55:6161–6165. 1995.PubMed/NCBI
|
|
23
|
Birk DM, Barbato J, Mureebe L and Chaer
RA: Current insights on the biology and clinical aspects of VEGF
regulation. Vasc Endovascular Surg. 42:517–530. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dvorak HF, Brown LF, Detmar M and Dvorak
AM: Vascular permeability factor/vascular endothelial growth
factor, micro-vascular hyperpermeability, and angiogenesis. Am J
Pathol. 146:1029–1039. 1995.PubMed/NCBI
|
|
25
|
Fujio Y and Walsh K: Akt mediates
cytoprotection of endothelial cells by vascular endothelial growth
factor in an anchorage-dependent manner. J Biol Chem.
274:16349–16354. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Claffey KP, Brown LF, del Aguila LF,
Tognazzi K, Yeo KT, Manseau EJ and Dvorak HF: Expression of
vascular permeability factor/vascular endothelial growth factor by
melanoma cells increases tumor growth, angiogenesis, and
experimental metastasis. Cancer Res. 56:172–181. 1996.
|
|
27
|
Miyata Y, Koga S, Kanda S, Nishikido M,
Hayashi T and Kanetake H: Expression of cyclooxygenase-2 in renal
cell carcinoma: correlation with tumor cell proliferation,
apoptosis, angiogenesis, expression of matrix metalloproteinase-2,
and survival. Clin Cancer Res. 9:1741–1749. 2003.
|
|
28
|
Wu G, Mannam AP, Wu J, Kirbis S, Shie JL,
Chen C, Laham RJ, Sellke FW and Li J: Hypoxia induces
myocyte-dependent COX-2 regulation in endothelial cells: role of
VEGF. Am J Physiol Heart Circ Physiol. 285:2420–2429. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wu G, Luo J, Rana JS, Laham R, Sellke FW
and Li J: Involvement of COX-2 in VEGF-induced angiogenesis via P38
and JNK pathways in vascular endothelial cells. Cardiovasc Res.
69:512–519. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang A, Meng L, Wang Q, Xi L, Chen G,
Wang S, Zhou J, Lu Y and Ma D: Enhanced in vitro invasiveness of
ovarian cancer cells through up-regulation of VEGF and induction of
MMP-2. Oncol Rep. 15:831–836. 2006.PubMed/NCBI
|
|
31
|
Yao JS, Chen Y, Zhai W, Xu K, Young WL and
Yang GY: Minocycline exerts multiple inhibitory effects on vascular
endothelial growth factor-induced smooth muscle cell migration.
Circ Res. 95:364–371. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Giatromanolaki A, Koukourakis MI,
Kakolyris S, Turley H, O’Byrne K, Scott PA, Pezzella F, Georgoulias
V, Harris AL and Gatter KC: Vascular endothelial growth factor,
wild-type p53, and angiogenesis in early operable non-small cell
lung cancer. Clin Cancer Res. 4:3017–3024. 1998.PubMed/NCBI
|
|
33
|
Ambs S, Bennett WP, Merriam WG, Ogunfusika
MO, Oser SM, Khan MA, Jones RT and Harris CC: Vascular endothelial
growth factor and nitric oxide synthase expression in human lung
cancer and the relation to p53. Br J Cancer. 78:233–239. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cavazzola LT, Rosa AR, Schirmer CC, Gurski
RR, Telles JP, Mielke F, Meurer L, Edelweiss MI and Kruel CD:
Immunohistochemical evaluation for P53 and VEGF (Vascular
Endothelial Growth Factor) is not prognostic for long term survival
in end stage esophageal adenocarcinoma. Rev Col Bras Cir. 36:24–34.
2009. View Article : Google Scholar
|
